Maple Leaf Green World (TSXV:MGW; OTCQB:MGWFF) (“Maple Leaf” or the “Company”) is pleased to announce that it has closed its upsized non-brokered private placement, which was conditionally approved by the TSX Venture Exchange (the “TSXV”) on April 28, 2017, and previously announced in its press releases dated March 17, 2017, March 21, 2017 and May 1, 2017. The Company has issued an aggregate of 13,216,070 units (“Units”) at a price of $0.55 per Unit for aggregate gross proceeds of $7,268,838.50 (the “Offering”). Each Unit consists of one common share of Maple Leaf (“Common Shares”) and one Common Share purchase warrant (“Warrants”). Each whole Warrant is exercisable into one Common Share at a price of $0.85 per Common Share until May 4, 2019. The Offering is subject to the receipt of final approval of the TSXV. The securities issued under the Offering are subject to a four-month hold period in accordance with applicable Canadian securities laws.
The Company has paid to certain finders a fee equal to 7% of the proceeds raised from subscribers to the Offering introduced to the Corporation by such finders.
The Corporation intends to use the net proceeds from the Offering to advance its engineering and construction plans for its proposed cannabis growing facility in Telkwa, British Columbia. Remaining proceeds, if any, will be used for general corporate purposes.
For further information regarding Maple Leaf Green World Inc., please visit  www.mlgreenworld.com.
 
About Maple Leaf Green World Inc.
Maple Leaf is a public Canadian company that focuses on the cannabis industry in North America. With over 10 years of extensive greenhouse management experience, it applies its eco- agriculture knowledge and cultivation technology to produce contaminant-free organic cannabis products. Maple Leaf’s long-term objective is to produce cannabis oil and export its products to approved countries.
Cautionary Statement
This news release includes certain statements that may be deemed “forward-looking statements” within the meaning of applicable Canadian securities legislation. Specifically, this news release includes, but is not limited to, forward-looking statements with respect to the net proceeds from the Offering and the use thereof, the completion of the Offering, the receipt of regulatory approvals and the timing thereof and the anticipated closing date of the Offering. Generally, forward-looking statements can be identified by the forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “projects”, “intends”, “anticipates”, or “does not anticipate”, or “believes”, or “variations of such words and phrases or state that certain actions, events or results “may”, “can”, “could”, “would”, “might”, or “will” be taken”, “occur” or “be achieved”. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements, including but not limited to: risks related to the development and operation of the Company’s projects, risks associated with general economic conditions, adverse industry events, marketing costs, loss of markets, future legislative and regulatory developments involving medical cannabis, inability to access sufficient capital from internal and external sources and/or inability to access sufficient capital on favourable terms, the medical cannabis industry in Canada and the jurisdictions where the Company operates generally, income tax and regulatory matters, competition, crop failure, currency and interest rate fluctuations, regulatory approvals including approvals from the TSXV for the Offering, and those factors discussed in the sections relating to risk factors of our business filed in the Company’s required securities filings on SEDAR. Although the Company has attempted to identify important factors that could cause results to differ materially from those contained in forward-looking statements, there may be other factors that cause results to be materially different from those anticipated, described, estimated, assessed or intended. There can be no assurance that any forward-looking statements will prove accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Company does not undertake to update any forward-looking statements that are incorporated by reference herein, except in accordance with applicable securities laws.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
THE SECURITIES OFFERED HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES ABSENT REGISTRATION OR AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS. THIS PRESS RELEASE SHALL NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY NOR SHALL THERE BE ANY SALE OF THE SECURITIES IN ANY STATE IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL.
 
Contact:
Maple Leaf Green World Inc. Raymond Lai
Chairman, President & CEO
+1(403) 452-4552
+1(403) 452-6900
rlai@mlgreenworld.com www.mlgreenworld.com
Click here to connect with Maple Leaf Green World (TSXV:MGW; OTCQB:MGWFF) to receive an Investor Presentation.

Source: docs.google.com


/NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES /

  4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) is pleased to announce that it has completed its previously announced bought deal prospectus offering (the ” Offering “) of units of the Company (” Units “), for aggregate gross proceeds of C$17,251,150 including full exercise of the over-allotment option granted to the underwriters in connection therewith.

Keep reading... Show less

Khiron Life Sciences Corp. (“ Khiron ” or, the “ Company ”) (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), announced today that it has re-filed its unaudited condensed interim consolidated financial statements, together with the notes thereto, for the three and six months ended June 30, 2020 and 2019 (the “ Interim Financial Statements ”) to correct, among other things, certain 2019 comparative period information and to update certain presentation arising from the Company’s early adoption of IFRS 3 in late 2019, which changes were identified in connection with the Company’s review engagement with its auditor. The Company does not consider these adjustments either individually nor in the aggregate, to be material.

The re-filed Interim Financial Statements reflect changes to the Condensed Interim Consolidated Statements of Loss and Comprehensive Loss comparative period to remove transaction fees from the income statement and capitalize them to the applicable acquisition in accordance with the Company’s early adoption of the amended IFRS 3 as set out in Note 2, and to reclassify $1 million from general and administrative expenses to transaction fees for presentation purposes to conform with the Company’s presentation used in its audited consolidated financial statements for the years ended December 31, 2019 and 2018 (the “ Audited Annual Financial Statements ”). The re-filed interim Financial Statements also reflect changes to the Condensed Interim Consolidated Statement of Changes in Shareholders’ Equity to correct the 2019 comparative period balances as they incorrectly reflect Q1 2019 period balances, update certain presentation to conform with the Company’s presentation used in its Audited Annual Financial Statements; and reduce the valuation conclusion of the Company’s acquisition of NettaGrowth International Inc. to conform with the Audited Annual Financial Statements. The re-filed Interim Financial Statements also bring forward the subsequent event note disclosure.

Keep reading... Show less

Part of “Rooted in Good” CSR Platform, “Feed the Block” Gives Back Through Strategic Social Partnerships with Local Organizations Focused on Food Insecurity

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading U.S. provider of consumer products in cannabis, today announced a multi-state fundraising initiative in which proceeds will benefit 24 locally run food banks, homeless shelters and nonprofits working to proactively address the needs of those facing food insecurity in communities across America. This effort is a part of the Strategic Social Partnerships pillar within Curaleaf’s “Rooted in Good” Corporate Social Responsibility platform.

Keep reading... Show less

On September 8, 2020, Aurora Cannabis Inc. (NYSE:ACB) stunned the market when it announced that it expected to record up to $1.8 billion in goodwill impairment charges in the fourth quarter of 2020. On the same day, Aurora also announced a charge of approximately $140 million in the carrying value of certain inventory, and that it was appointing a new chief executive officer. On this news, Aurora’s stock fell approximately 11.6% in just one day. Since May 2020, Aurora’s stock is down approximately $10.00 per share

A lawsuit alleging violations of federal securities laws has been filed against Aurora and certain of its officers and directors. The suit alleges, among other things, that Aurora misled investors as to the value of prior acquisitions, that the Company had experienced degradation in certain assets, and that as a result, it was foreseeable that Aurora would record significant goodwill and asset impairment charges. According to the lawsuit, this news was so shocking because Aurora had previously lauded a “business transformation plan” that would purportedly “better align the business financially with the current realities of the cannabis market.”

Keep reading... Show less

  • Exclusive patent licensed from University of Idaho.
  • Mustard-derived fumigation of stored food – targeting vegetables and potatoes.
  • Leading agrochemical for sprout suppression – chlorpropham – banned by European Union on Oct. 8, 2020.
  • Appointment of Scientific Advisor Dr. Matthew J. Morra, professor emeritus of soil biochemistry at University of Idaho.

 MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the “Company”, “MustGrow”) is pleased to announce the exclusive patent licensing from the University of Idaho pertaining to a natural biopesticide mustard-based treatment of stored produce and other foods, particularly sprout suppression of potatoes.

Keep reading... Show less